Free Trial
NASDAQ:VTVT

vTv Therapeutics 11/9/2023 Earnings Report

vTv Therapeutics logo
$19.74 +0.93 (+4.91%)
As of 04/17/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

vTv Therapeutics EPS Results

Actual EPS
-$3.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

vTv Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

vTv Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

vTv Therapeutics' next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

vTv Therapeutics Earnings Headlines

Equities Analysts Issue Forecasts for VTVT Q1 Earnings
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
vTv Therapeutics (NASDAQ:VTVT) Now Covered by HC Wainwright
vTv Therapeutics initiated with a Buy at H.C. Wainwright
See More vTv Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like vTv Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on vTv Therapeutics and other key companies, straight to your email.

About vTv Therapeutics

vTv Therapeutics (NASDAQ:VTVT), a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

View vTv Therapeutics Profile

More Earnings Resources from MarketBeat